Adasuve Approved for Agitation Associated with Schizophrenia or Bipolar I Disorder

Monthly Prescribing Reference (12/12)
Alexza Pharmaceuticals has announced that Adasuve has received the Food and Drug Administration's approval for use in the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Approval was based on two Phase 3 trials that found that Adasuve was effective in the acute treatment of agitation in adults with schizophrenia or bipolar I disorder. The drug is expected to be available as single-use disposable inhalers containing 10 mg of loxapine in 5-unit cartons during the third quarter of 2013.

Read the complete article


Share |

Sponsor Highlights

inPharmacyJobs